Automate Your Wheel Strategy on PODD
With Tiblio's Option Bot, you can configure your own wheel strategy including PODD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PODD
- Rev/Share 35.8392
- Book/Share 19.6712
- PB 16.2853
- Debt/Equity 0.0577
- CurrentRatio 2.8708
- ROIC 0.1809
- MktCap 22535629415.0
- FreeCF/Share 5.9858
- PFCF 53.5034
- PE 91.56
- Debt/Assets 0.0264
- DivYield 0
- ROE 0.1827
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | PODD | Stifel | -- | Buy | -- | $370 | Oct. 21, 2025 |
| Resumed | PODD | Oppenheimer | -- | Outperform | -- | $365 | Sept. 8, 2025 |
| Initiation | PODD | Truist | -- | Buy | -- | $365 | June 16, 2025 |
| Initiation | PODD | Goldman | -- | Buy | -- | $380 | May 30, 2025 |
| Upgrade | PODD | Wolfe Research | Peer Perform | Outperform | -- | $350 | May 13, 2025 |
| Downgrade | PODD | Wolfe Research | Outperform | Peer Perform | -- | -- | April 29, 2025 |
| Initiation | PODD | RBC Capital Mkts | -- | Outperform | -- | $340 | March 6, 2025 |
News
Insulet (PODD) Upgraded to Strong Buy: Here's What You Should Know
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet (PODD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet (PODD) could produce exceptional returns because of its solid growth attributes.
Read More
Insulet Corporation (PODD) Q3 2025 Earnings Call Transcript
Published: November 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Insulet Corporation ( PODD ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Clare Trachtman - Vice President of Investor Relations Ashley McEvoy - CEO, President & Director Flavia Pease - Executive VP & CFO Eric Benjamin - Executive VP & COO Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Joanne Wuensch - Citigroup Inc., Research Division Travis Steed - BofA Securities, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Michael Polark - Wolfe Research, LLC Gursimran Kaur …
Read More
Insulet (PODD) Reports Q3 Earnings: What Key Metrics Have to Say
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Final Trades: Insulet Corp, Uber and Apollo Global
Published: November 04, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Ahead of Insulet (PODD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Read More
Insulet (PODD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.
Read More
Here's Why Insulet (PODD) is a Strong Momentum Stock
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Insulet Corporation (PODD) Presents At Baird Global Healthcare Conference 2025 Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Insulet Corporation (NASDAQ:PODD ) Baird Global Healthcare Conference 2025 September 9, 2025 12:15 PM EDT Company Participants Eric Benjamin - Executive VP & COO Ana Chadwick - Executive VP & CFO Conference Call Participants Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Presentation Jeffrey Johnson Senior Research Analyst Jeff Johnson.
Read More
Here's Why Insulet (PODD) is a Strong Growth Stock
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Insulet Gains 77.2% in a Year: What's Driving the Rally?
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
PODD's 77.2% stock surge is fueled by Omnipod 5 expansion, global launches, strong Q2 profits and robust financial stability.
Read More
Final Trades: Rocket Companies, Cisco Systems, Insulet Corp and the IGV
Published: August 19, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.
Read More
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Insulet Corporation (NASDAQ:PODD ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Ana Maria Chadwick - Executive VP & CFO Ashley A. McEvoy - CEO, President & Director Eric Benjamin - Executive VP, Chief Product & Customer Experience Officer June Lazaroff - Senior Director of Investor Relations Conference Call Participants Danielle Joy Antalffy - UBS Investment Bank, Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division Issie Kirby - Redburn (Europe) Limited, Research Division Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division Jeffrey D.
Read More
Insulet (PODD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Insulet (PODD) Surpasses Q2 Earnings and Revenue Estimates
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet (PODD) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.55 per share a year ago.
Read More
Curious about Insulet (PODD) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here's Why You Should Retain PODD Stock in Your Portfolio Now
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.
Read More
Here's Why Insulet (PODD) is a Strong Growth Stock
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
S&P 500 Wraps Up Best May Since 1990: 5 Top Stocks in the ETF
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
SPY jumped 6.3% in May, the most in decades, led by standout gains in NRG, STX, CEG, PODD and MCHP amid easing trade fears.
Read More
Insulet Gains 78.5% in a Year: What's Driving the Stock?
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds.
Read More
About Insulet Corporation (PODD)
- IPO Date 2007-05-15
- Website https://www.insulet.com
- Industry Medical - Devices
- CEO Ashley A. McEvoy
- Employees 3900